Microdosing and Customized Titration One recent trend is the exploration of microdosing, using smaller, carefully calibrated doses of semaglutide to achieve benefits with potentially fewer side effects
SkinnyRx's published website references self-reported outcomes among a subset of members specifically noting an average of 29.3 lbs lost in the first six months based on self-reported data from 111 members on GLP-1 injections combined with diet and exercise
Compounding pharmacists had long known that the shortage had a shelf-life, according to the compounding trade group, which claimed it's been "prepping patients for months to expect that eventuality
The STEP 1 trial data shows that participants on semaglutide experienced a roughly linear weight loss trajectory through the first 60 weeks, with the steepest decline occurring once therapeutic doses were reached
Lixisenatide, sold under the brand name Adlyxin, belongs to the GLP-1 receptor agonist class and helps manage type 2 diabetes